Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project

Holly J. Meany; Wendy B. London; Peter F. Ambros; Katherine K. Matthay; Tom Monclair; Thorsten Simon; Alberto Garaventa; Frank Berthold; Akira Nakagawara; Susan L. Cohn; Andrew D J Pearson; Julie R. Park

doi:10.1002/pbc.25134

Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project

Holly J. Meany, Wendy B. London, Peter F. Ambros, Katherine K. Matthay, Tom Monclair, Thorsten Simon, Alberto Garaventa, Frank Berthold, Akira Nakagawara, Susan L. Cohn, Andrew D J Pearson, Julie R. Park

Istituto "Giannina Gaslini"

Research output: Contribution to journal › Article › peer-review

Abstract

Background: International Neuroblastoma Staging System (INSS) Stage 3 neuroblastoma is a heterogeneous disease. Data from the International Neuroblastoma Risk Group (INRG) database were analyzed to define patient and tumor characteristics predictive of outcome. Procedure: Of 8,800 patients in the INRG database, 1,483 with INSS Stage 3 neuroblastoma and complete follow-up data were analyzed. Secondary analysis was performed in 1,013 patients (68%) with MYCN-non-amplified (NA) tumors. Significant prognostic factors were identified via log-rank test comparisons of survival curves. Multivariable Cox proportional hazards regression model was used to identify factors independently predictive of event-free survival (EFS). Results: Age at diagnosis (P

Original language	English
Pages (from-to)	1932-1939
Number of pages	8
Journal	Pediatric Blood and Cancer
Volume	61
Issue number	11
DOIs	https://doi.org/10.1002/pbc.25134
Publication status	Published - Nov 1 2014

Keywords

Biologic factor
Neuroblastoma
Treatment outcome

ASJC Scopus subject areas

Oncology
Pediatrics, Perinatology, and Child Health
Hematology

Access to Document

10.1002/pbc.25134

Cite this

Meany, H. J., London, W. B., Ambros, P. F., Matthay, K. K., Monclair, T., Simon, T., Garaventa, A., Berthold, F., Nakagawara, A., Cohn, S. L., Pearson, A. D. J., & Park, J. R. (2014). Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project. Pediatric Blood and Cancer, 61(11), 1932-1939. https://doi.org/10.1002/pbc.25134

Significance of clinical and biologic features in Stage 3 neuroblastoma : A report from the International Neuroblastoma Risk Group project. / Meany, Holly J.; London, Wendy B.; Ambros, Peter F.; Matthay, Katherine K.; Monclair, Tom; Simon, Thorsten; Garaventa, Alberto; Berthold, Frank; Nakagawara, Akira; Cohn, Susan L.; Pearson, Andrew D J; Park, Julie R.

In: Pediatric Blood and Cancer, Vol. 61, No. 11, 01.11.2014, p. 1932-1939.

Research output: Contribution to journal › Article › peer-review

Meany, HJ, London, WB, Ambros, PF, Matthay, KK, Monclair, T, Simon, T, Garaventa, A, Berthold, F, Nakagawara, A, Cohn, SL, Pearson, ADJ & Park, JR 2014, 'Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project', Pediatric Blood and Cancer, vol. 61, no. 11, pp. 1932-1939. https://doi.org/10.1002/pbc.25134

Meany, Holly J. ; London, Wendy B. ; Ambros, Peter F. ; Matthay, Katherine K. ; Monclair, Tom ; Simon, Thorsten ; Garaventa, Alberto ; Berthold, Frank ; Nakagawara, Akira ; Cohn, Susan L. ; Pearson, Andrew D J ; Park, Julie R. / Significance of clinical and biologic features in Stage 3 neuroblastoma : A report from the International Neuroblastoma Risk Group project. In: Pediatric Blood and Cancer. 2014 ; Vol. 61, No. 11. pp. 1932-1939.

@article{0ec12c41032f423eac356f53dcad9da0,

title = "Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project",

abstract = "Background: International Neuroblastoma Staging System (INSS) Stage 3 neuroblastoma is a heterogeneous disease. Data from the International Neuroblastoma Risk Group (INRG) database were analyzed to define patient and tumor characteristics predictive of outcome. Procedure: Of 8,800 patients in the INRG database, 1,483 with INSS Stage 3 neuroblastoma and complete follow-up data were analyzed. Secondary analysis was performed in 1,013 patients (68%) with MYCN-non-amplified (NA) tumors. Significant prognostic factors were identified via log-rank test comparisons of survival curves. Multivariable Cox proportional hazards regression model was used to identify factors independently predictive of event-free survival (EFS). Results: Age at diagnosis (P",

keywords = "Biologic factor, Neuroblastoma, Treatment outcome",

author = "Meany, {Holly J.} and London, {Wendy B.} and Ambros, {Peter F.} and Matthay, {Katherine K.} and Tom Monclair and Thorsten Simon and Alberto Garaventa and Frank Berthold and Akira Nakagawara and Cohn, {Susan L.} and Pearson, {Andrew D J} and Park, {Julie R.}",

year = "2014",

month = nov,

day = "1",

doi = "10.1002/pbc.25134",

language = "English",

volume = "61",

pages = "1932--1939",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "John Wiley and Sons Inc.",

number = "11",

}

TY - JOUR

T1 - Significance of clinical and biologic features in Stage 3 neuroblastoma

T2 - A report from the International Neuroblastoma Risk Group project

AU - Meany, Holly J.

AU - London, Wendy B.

AU - Ambros, Peter F.

AU - Matthay, Katherine K.

AU - Monclair, Tom

AU - Simon, Thorsten

AU - Garaventa, Alberto

AU - Berthold, Frank

AU - Nakagawara, Akira

AU - Cohn, Susan L.

AU - Pearson, Andrew D J

AU - Park, Julie R.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Background: International Neuroblastoma Staging System (INSS) Stage 3 neuroblastoma is a heterogeneous disease. Data from the International Neuroblastoma Risk Group (INRG) database were analyzed to define patient and tumor characteristics predictive of outcome. Procedure: Of 8,800 patients in the INRG database, 1,483 with INSS Stage 3 neuroblastoma and complete follow-up data were analyzed. Secondary analysis was performed in 1,013 patients (68%) with MYCN-non-amplified (NA) tumors. Significant prognostic factors were identified via log-rank test comparisons of survival curves. Multivariable Cox proportional hazards regression model was used to identify factors independently predictive of event-free survival (EFS). Results: Age at diagnosis (P

AB - Background: International Neuroblastoma Staging System (INSS) Stage 3 neuroblastoma is a heterogeneous disease. Data from the International Neuroblastoma Risk Group (INRG) database were analyzed to define patient and tumor characteristics predictive of outcome. Procedure: Of 8,800 patients in the INRG database, 1,483 with INSS Stage 3 neuroblastoma and complete follow-up data were analyzed. Secondary analysis was performed in 1,013 patients (68%) with MYCN-non-amplified (NA) tumors. Significant prognostic factors were identified via log-rank test comparisons of survival curves. Multivariable Cox proportional hazards regression model was used to identify factors independently predictive of event-free survival (EFS). Results: Age at diagnosis (P

KW - Biologic factor

KW - Neuroblastoma

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=84915792866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84915792866&partnerID=8YFLogxK

U2 - 10.1002/pbc.25134

DO - 10.1002/pbc.25134

M3 - Article

C2 - 25044743

AN - SCOPUS:84915792866

VL - 61

SP - 1932

EP - 1939

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 11

ER -

Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this